Artificial Intelligence and Pathomics: Prostate Cancer

Urol Clin North Am. 2024 Feb;51(1):15-26. doi: 10.1016/j.ucl.2023.06.001. Epub 2023 Jul 25.ABSTRACTArtificial intelligence (AI) has the potential to transform pathologic diagnosis and cancer patient management as a predictive and prognostic biomarker. AI-based systems can be used to examine digitally scanned histopathology slides and differentiate benign from malignant cells and low from high grade. Deep learning models can analyze patient data from individual or multimodal combinations and identify patterns to be used to predict the response to different therapeutic options, the risk of recurrence or progression, and the prognosis of the newly diagnosed patient. AI-based models will improve treatment planning for patients with prostate cancer and improve the efficiency and cost-effectiveness of the pathology laboratory.PMID:37945099 | DOI:10.1016/j.ucl.2023.06.001
Source: The Urologic Clinics of North America - Category: Urology & Nephrology Authors: Source Type: research